Warfarin Sodium (CAS 129-06-6)
See product citations (3)
QUICK LINKS
Warfarin Sodium operates as a potent inhibitor of two enzymes, Vitamin K Epoxide Reductase (VKOR) and Cytochrome P450 2C9 (CYP2C9), showcasing its significant role in the biochemical pathways related to coagulation and drug metabolism. The inhibition of VKOR is central to Warfarin′s primary mechanism of action, as this enzyme is essential for the cyclic conversion of vitamin K and its epoxide form. By hindering VKOR activity, Warfarin Sodium effectively reduces the regeneration of vitamin K1, thereby depleting functional vitamin K reserves. This depletion directly impacts the gamma-carboxylation of vitamin K-dependent clotting factors II, VII, IX, and X, along with regulatory proteins C and S, leading to an anticoagulant effect by diminishing the clotting cascade′s efficiency.
Warfarin Sodium (CAS 129-06-6) References
- Tinzaparin sodium: a low-molecular-weight heparin. | Neely, JL., et al. 2002. Am J Health Syst Pharm. 59: 1426-36. PMID: 12166042
- Duration of warfarin sodium therapy prior to electrical cardioversion of atrial fibrillation. | Ryman, J., et al. 2003. J Intern Med. 253: 76-80. PMID: 12588539
- Warfarin sodium. Practitioner beware. | Bernard, JM., et al. 1992. J Am Podiatr Med Assoc. 82: 345-51. PMID: 1432651
- Effect of sodium warfarin on vitamin K-dependent proteins and skeletal development in the rat fetus. | Feteih, R., et al. 1990. J Bone Miner Res. 5: 885-94. PMID: 2239372
- Warfarin sodium for anticoagulation of atherosclerotic miniature swine. | Cromeens, DM., et al. 1990. J Invest Surg. 3: 141-5. PMID: 2285674
- Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions. | Martinez, JF., et al. 1997. Int J Pharm Compd. 1: 356-8. PMID: 23989380
- Quantifying low levels (
- Oral disintegrating patient-tailored tablets of warfarin sodium produced by 3D printing. | Tian, P., et al. 2018. Drug Dev Ind Pharm. 44: 1918-1923. PMID: 30027774
- Stability of warfarin sodium flavoured preservative-free oral liquid formulations. | Schlatter, J. and Cisternino, S. 2018. Eur J Hosp Pharm. 25: e98-e101. PMID: 31157077
- Molecular Insights into Warfarin Sodium 2-Propanol Solvate Solid Form Changes and Disproportionation Using a Low Volume Two-Stage Dissolution Approach. | Shah, HS., et al. 2021. Mol Pharm. 18: 1779-1791. PMID: 33689375
- Synthesis of nickel-doped ceria nanospheres for in situ profiling of Warfarin sodium in biological media. | Maheshwaran, S., et al. 2022. Bioelectrochemistry. 146: 108166. PMID: 35643022
- Vaccine-drug interactions. | D'Arcy, PF. 1984. Drug Intell Clin Pharm. 18: 697-700. PMID: 6383754
- Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions. | Stratton, JR. 1995. West J Med. 163: 177-9. PMID: 7571577
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Warfarin Sodium, 1 g | sc-204941 | 1 g | $32.00 | |||
Warfarin Sodium, 10 g | sc-204941A | 10 g | $72.00 |